These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22382876)

  • 1. Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.
    Staff C; Magnusson CG; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frödin JE; Wahrén B; Mellstedt H; Ullenhag GJ
    J Clin Immunol; 2012 Aug; 32(4):855-65. PubMed ID: 22382876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.
    Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
    Clin Cancer Res; 2004 May; 10(10):3273-81. PubMed ID: 15161680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.
    Samanci A; Yi Q; Fagerberg J; Strigård K; Smith G; Rudén U; Wahren B; Mellstedt H
    Cancer Immunol Immunother; 1998 Nov; 47(3):131-42. PubMed ID: 9829838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
    Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
    Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen.
    Ullenhag GJ; Frödin JE; Strigård K; Mellstedt H; Magnusson CG
    Cancer Res; 2002 Mar; 62(5):1364-9. PubMed ID: 11888906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
    Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
    J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.
    Conry RM; Allen KO; Lee S; Moore SE; Shaw DR; LoBuglio AF
    Clin Cancer Res; 2000 Jan; 6(1):34-41. PubMed ID: 10656429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).
    Lima J; Jenkins C; Guerrero A; Triozzi PL; Shaw DR; Strong TV
    Vaccine; 2005 Jan; 23(10):1273-83. PubMed ID: 15652670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
    Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
    Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
    Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
    Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
    Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells.
    Zhao J; Kuroki M; Shibaguchi H; Wang L; Huo Q; Takami N; Tanaka T; Kinugasa T; Kuroki M
    Oncol Res; 2008; 17(5):217-22. PubMed ID: 18980018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer.
    Hallermalm K; Johansson S; Bråve A; Ek M; Engström G; Boberg A; Gudmundsdotter L; Blomberg P; Mellstedt H; Stout R; Liu MA; Wahren B
    Scand J Immunol; 2007 Jul; 66(1):43-51. PubMed ID: 17587345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.
    Staff C; Mozaffari F; Haller BK; Wahren B; Liljefors M
    Vaccine; 2011 Sep; 29(39):6817-22. PubMed ID: 21195077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA.
    Ullenhag GJ; Fagerberg J; Strigård K; Frödin JE; Mellstedt H
    Cancer Immunol Immunother; 2004 Apr; 53(4):331-7. PubMed ID: 14605762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
    Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
    Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.